Skip to main content

Disappointing study results for vTv Therapeutics

vTv Therapeutics Inc. (Nasdaq: VTVT) reported disappointing results from a Phase 3 STEADFAST study of its Alzheimer's treatment azeliragon sending the stock price plummeting $2.54 to close at $0.71.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.